Learn About Velsipity for Ulcerative Colitis

What Is Velsipity and How Does It Work for Ulcerative Colitis

Velsipity is a medication approved by the U.S. Food and Drug Administration (FDA) in December 2023 for treating ulcerative colitis, a type of inflammatory bowel disease (IBD). The drug works by targeting a specific protein in the body called S1P1, which plays a role in how immune cells move throughout the body. By affecting this protein, Velsipity helps reduce the movement of certain immune cells into the colon and rectum, where they cause inflammation and damage in people with ulcerative colitis.

Pay Your Lowe's Credit Card Bill Online →

The medication is taken as an oral tablet, meaning you swallow it by mouth rather than receiving an injection or infusion. This differs from some other ulcerative colitis treatments that require intravenous infusions at a hospital or clinic. Velsipity is manufactured by Pfizer and belongs to a class of drugs called S1P receptor modulators. This class of medication has been used to treat other conditions, including multiple sclerosis, giving researchers insight into how it affects the immune system.

Understanding how Velsipity works matters because it shows why the medication may help different people than other treatments do. Some patients don't respond well to biologic medications, which are drugs made from living cells. Others cannot tolerate the side effects of different treatments. Velsipity offers an alternative approach that works through a different mechanism in the body. Clinical trials showed that people taking Velsipity experienced fewer symptoms, including reduced diarrhea, urgency to use the bathroom, and rectal bleeding compared to those taking a placebo.

Practical takeaway: Velsipity represents a newer treatment option for ulcerative colitis that works differently from older medications. Discussing whether this medication might be suitable for your situation requires a conversation with your gastroenterologist or IBD specialist.

Clinical Trial Results and Effectiveness Data

The FDA approval of Velsipity was based on data from clinical trials involving people with moderate to severe ulcerative colitis. In the main trial, called DIALOGUE-1, researchers followed patients for 52 weeks. The results showed that 47% of patients taking Velsipity achieved clinical remission by week 52, meaning they had very few or no symptoms of ulcerative colitis. This compared to 21% of patients taking a placebo, or inactive pill.

Learn About COPD Treatment Options in Colorado →

Clinical remission specifically means having fewer than three bowel movements per day, no blood in the stool, and a rectal bleeding score of zero. Some patients also achieved what researchers call endoscopic remission, which means the lining of the colon looks healthier when examined with a camera during a colonoscopy. About 37% of Velsipity patients achieved endoscopic remission compared to 9% of those taking placebo.

The trial also measured something called response rates, which indicate whether patients had improvement even if they didn't reach complete remission. Among Velsipity patients, 62% experienced a clinical response within 52 weeks. A clinical response means at least a 3-point improvement on a scoring system that measures ulcerative colitis severity. The results were consistent across different groups of patients, regardless of whether they had taken biologic medications before or were treatment-naive, meaning they hadn't tried these stronger medications previously.

It's important to note that not every patient responds to Velsipity. Some patients experienced no improvement, while others had partial responses. Response rates also varied based on disease severity at the start of treatment. Patients with moderate disease showed higher response rates than those with severe disease. Individual factors, including overall health status, other medications, and how long a person had ulcerative colitis, influenced how well the medication worked.

Practical takeaway: Velsipity showed meaningful improvement in symptoms for a significant portion of trial participants, but individual results vary. Your doctor can discuss whether the trial results suggest this medication might help your specific situation.

Dosing, Administration, and Daily Use

Velsipity comes as an oral tablet that patients take by mouth once daily. The standard approved dose is 2 mg, taken as one tablet each day. Unlike some other ulcerative colitis treatments that require infusions at medical facilities or frequent injections, Velsipity's tablet form allows most people to take it at home as part of their daily routine. This convenience factor can make it easier for some patients to stick with their treatment plan, since missing doses is less likely when medication is simple to access.

Learn About Contacting Illinois Secretary of State DMV →

The medication can be taken with or without food, though taking it consistently the same way each day helps maintain steady medication levels in your body. Patients should swallow the tablet whole without crushing, splitting, or chewing it. This is important because the tablet's design ensures the medication is released in the right way as it moves through your digestive system. Some patients set phone reminders or use pill organizers to remember their daily dose.

Starting Velsipity typically doesn't involve a gradual dose increase. Patients begin with the full 2 mg dose right away, unlike some other medications that require starting at a lower dose and increasing over time. However, before starting Velsipity, patients need blood tests and screening for certain infections. Doctors check for a history of chickenpox or herpes zoster (shingles) because Velsipity can affect how the immune system handles these viruses. Blood pressure monitoring is also recommended, as the medication can slightly raise blood pressure in some patients.

During treatment, patients typically need follow-up appointments and lab work to monitor how well the medication is working and to watch for side effects. Some patients feel improvement in symptoms within weeks, while others take several weeks or longer to notice benefits. Doctors generally want to give Velsipity at least 12 weeks before deciding whether it's working adequately for an individual patient.

Practical takeaway: Velsipity's once-daily tablet form is simpler than some other ulcerative colitis treatments, but it requires baseline testing and ongoing monitoring by your healthcare provider.

Potential Side Effects and Safety Considerations

Like all medications, Velsipity can cause side effects. In clinical trials, the most common side effects were upper respiratory infections, such as colds or sinus infections, which occurred in about 25% of Velsipity patients compared to 16% of those taking placebo. Other relatively common side effects included back pain, high blood pressure, weight gain, and headaches. Most side effects were mild to moderate in severity, and many improved over time as patients' bodies adjusted to the medication.

Get Your Free Monitor Resolution Guide →

More serious but less common side effects are important to understand. Velsipity can lower the white blood cell count, which helps fight infections. Because of this, patients taking Velsipity have a higher risk of developing infections, including serious ones. Healthcare providers monitor white blood cell counts through regular blood tests. Patients should report signs of infection, such as fever, persistent cough, or unusual tiredness, to their doctor promptly.

The medication may also increase the risk of herpes zoster (shingles) reactivation in people with a history of chickenpox or shingles. Before starting Velsipity, doctors ask about this history and may recommend a shingles vaccine beforehand if someone hasn't received one. The medication can affect blood pressure, raising it slightly in some patients, so regular blood pressure monitoring is standard practice.

There are also specific contraindications, meaning situations where doctors won't prescribe Velsipity. Pregnant individuals should not take this medication, as it may harm a developing fetus. The medication passes into breast milk, so breastfeeding while taking Velsipity requires careful discussion with healthcare providers. Additionally, patients with active or recent infections should not start Velsipity until the infection clears, and those with certain types of heart conditions or severe immunosuppression need careful evaluation before using this medication.

Some patients experienced discontinuation of the medication due to side effects in clinical trials, though this happened in only a small percentage. Heart rhythm monitoring may be recommended for patients with certain risk factors. Regular communication with your healthcare team about any new symptoms or concerns is essential when taking this medication.

Practical takeaway: Velsipity requires baseline testing and ongoing monitoring to watch for infections and other side effects, but most side effects reported in trials were mild to moderate.

How Velsipity Compares to Other Ulcerative Colitis Treatments

Patients with ulcerative colitis have several

Learn About VA Disability Service Connection Options →